Skip to main content
NCBI home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1988 Apr;1(2):139–156. doi: 10.1128/cmr.1.2.139

Antibiotic combinations: should they be tested?

G M Eliopoulos 1, C T Eliopoulos 1
PMCID: PMC358039  PMID: 3069193

Abstract

When antibiotic combinations are used to provide a broader spectrum of antimicrobial activity or in an attempt to prevent the emergence of resistant organisms, it is rarely necessary or practical to perform tests of drug interactions in vitro. In vitro testing of combinations may be useful when combinations are used in an attempt to attain synergistic interactions. In some cases, screening methods can be used as substitutes for formal synergy testing. This paper examines the mechanisms of antibiotic interaction leading to synergism or antagonism, surveys attempts to correlate in vitro observations with efficacy in animal models, and reviews clinical data providing evidence for or against a useful role of synergistic antibiotic interactions in the treatment of human infections.

Full text

PDF
139

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alford R. H., Manian F. A. Current antimicrobial management of tuberculosis. Curr Clin Top Infect Dis. 1987;8:204–226. [PubMed] [Google Scholar]
  2. Allen N. E., Alborn W. E., Jr, Hobbs J. N., Jr, Kirst H. A. 7-Hydroxytropolone: an inhibitor of aminoglycoside-2"-O-adenylyltransferase. Antimicrob Agents Chemother. 1982 Nov;22(5):824–831. doi: 10.1128/aac.22.5.824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson E. T., Young L. S., Hewitt W. L. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy. 1978;24(1):45–54. doi: 10.1159/000237759. [DOI] [PubMed] [Google Scholar]
  4. Andriole V. T. Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin. J Infect Dis. 1974 Feb;129(2):124–133. doi: 10.1093/infdis/129.2.124. [DOI] [PubMed] [Google Scholar]
  5. Archer G. L. Antimicrobial susceptibility and selection of resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices. Antimicrob Agents Chemother. 1978 Sep;14(3):353–359. doi: 10.1128/aac.14.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Archer G., Fekety F. R., Jr Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. J Infect Dis. 1977 Sep;136(3):327–335. doi: 10.1093/infdis/136.3.327. [DOI] [PubMed] [Google Scholar]
  7. Aronoff S. C., Klinger J. D. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrob Agents Chemother. 1984 Feb;25(2):279–280. doi: 10.1128/aac.25.2.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Aronoff S. C., Shlaes D. M. Factors that influence the evolution of beta-lactam resistance in beta-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa. J Infect Dis. 1987 May;155(5):936–941. doi: 10.1093/infdis/155.5.936. [DOI] [PubMed] [Google Scholar]
  9. BONIFAS V. Détermination de l'association synergique binaire d'antibiotes et de sulfamides. Experientia. 1952 Jun 15;8(6):234–235. doi: 10.1007/BF02170729. [DOI] [PubMed] [Google Scholar]
  10. Backes R. J., Rouse M. S., Henry N. K., Geraci J. E., Wilson W. R. Activity of penicillin combined with an aminoglycoside against group B streptococci in vitro and in experimental endocarditis. J Antimicrob Chemother. 1986 Oct;18(4):491–498. doi: 10.1093/jac/18.4.491. [DOI] [PubMed] [Google Scholar]
  11. Baker C. N., Thornsberry C., Facklam R. R. Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci. Antimicrob Agents Chemother. 1981 May;19(5):716–725. doi: 10.1128/aac.19.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bamberger D. M., Peterson L. R., Gerding D. N., Moody J. A., Fasching C. E. Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. J Antimicrob Chemother. 1986 Jul;18(1):51–63. doi: 10.1093/jac/18.1.51. [DOI] [PubMed] [Google Scholar]
  13. Barry A. L., Ayers L. W., Gavan T. L., Gerlach E. H., Jones R. N. In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers. Eur J Clin Microbiol. 1984 Jun;3(3):203–206. doi: 10.1007/BF02014879. [DOI] [PubMed] [Google Scholar]
  14. Bayer A. S., Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985 Jan;151(1):157–165. doi: 10.1093/infdis/151.1.157. [DOI] [PubMed] [Google Scholar]
  15. Bayer A. S., Norman D., Kim K. S. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1985 Dec;28(6):781–785. doi: 10.1128/aac.28.6.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Berenbaum M. C. A method for testing for synergy with any number of agents. J Infect Dis. 1978 Feb;137(2):122–130. doi: 10.1093/infdis/137.2.122. [DOI] [PubMed] [Google Scholar]
  17. Bodey G. P., Alvarez M. E., Jones P. G., Rolston K. V., Steelhammer L., Fainstein V. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother. 1986 Aug;30(2):211–214. doi: 10.1128/aac.30.2.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Bodey G. P., Jadeja L., Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985 Sep;145(9):1621–1629. doi: 10.1001/archinte.145.9.1621. [DOI] [PubMed] [Google Scholar]
  19. Bornside G. H. Synergistic antibacterial activity of ampicillin-cloxacillin mixtures against Proteus morganii. Appl Microbiol. 1968 Oct;16(10):1507–1511. doi: 10.1128/am.16.10.1507-1511.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Briceland L. L., Pasko M. T., Mylotte J. M. Serum bactericidal rate as measure of antibiotic interactions. Antimicrob Agents Chemother. 1987 May;31(5):679–685. doi: 10.1128/aac.31.5.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Bryan L. E., Kwan S. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother. 1983 Jun;23(6):835–845. doi: 10.1128/aac.23.6.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Bulger R. J., Nielson K. In vitro evaluation of the hetacillin/dicloxacillin antibiotic combination. Am J Med Sci. 1968 Sep;256(3):155–165. doi: 10.1097/00000441-196809000-00004. [DOI] [PubMed] [Google Scholar]
  23. Bush K., Sykes R. B. beta-Lactamase inhibitors in perspective. J Antimicrob Chemother. 1983 Feb;11(2):97–107. doi: 10.1093/jac/11.2.97. [DOI] [PubMed] [Google Scholar]
  24. Bustamante C. I., Drusano G. L., Wharton R. C., Wade J. C. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agents Chemother. 1987 Apr;31(4):632–634. doi: 10.1128/aac.31.4.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. CATES J. E., CHRISTIE R. V., GARROD L. P. Penicillin-resistant subacute bacterial endocarditis treated by a combination of penicillin and streptomycin. Br Med J. 1951 Mar 31;1(4708):653–656. doi: 10.1136/bmj.1.4708.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. CHABBERT Y. A., PATTE J. C. Cellophane transfer: application to the study of activity of combinations of antibiotics. Appl Microbiol. 1960 Jul;8:193–199. doi: 10.1128/am.8.4.193-199.1960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. CHABBERT Y. A., WATERWORTH P. M. STUDIES ON THE "CARRY-OVER" OF ANTIBIOTICS USING THE CELLOPHANE TRANSFER TECHNIQUE. J Clin Pathol. 1965 May;18:314–316. doi: 10.1136/jcp.18.3.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Calandra T., Glauser M. P. Immunocompromised animal models for the study of antibiotic combinations. Am J Med. 1986 May 30;80(5C):45–52. [PubMed] [Google Scholar]
  29. Calderwood S. A., Wennersten C., Moellering R. C., Jr, Kunz L. J., Krogstad D. J. Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother. 1977 Sep;12(3):401–405. doi: 10.1128/aac.12.3.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Calderwood S. B., Wennersten C., Moellering R. C., Jr Resistance to antibiotic synergism in Streptococcus faecalis: further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin. Antimicrob Agents Chemother. 1981 Apr;19(4):549–555. doi: 10.1128/aac.19.4.549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Chadwick E. G., Shulman S. T., Yogev R. Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis. J Infect Dis. 1986 Oct;154(4):670–675. doi: 10.1093/infdis/154.4.670. [DOI] [PubMed] [Google Scholar]
  32. Chamovitz B., Bryant R. E., Gilbert D. N., Hartstein A. I. Prosthetic valve endocarditis caused by Staphylococcus epidermidis. Development of rifampin resistance during vancomycin and rifampin therapy. JAMA. 1985 May 17;253(19):2867–2868. [PubMed] [Google Scholar]
  33. Chan E. L., Zabransky R. J. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas. Diagn Microbiol Infect Dis. 1987 Feb;6(2):157–164. doi: 10.1016/0732-8893(87)90101-5. [DOI] [PubMed] [Google Scholar]
  34. Chandrasekar P. H., Crane L. R., Bailey E. J. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother. 1987 Mar;19(3):321–329. doi: 10.1093/jac/19.3.321. [DOI] [PubMed] [Google Scholar]
  35. Cockerill F. R., 3rd, Edson R. S. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1983 Mar;58(3):147–153. [PubMed] [Google Scholar]
  36. Comber K. R., Basker M. J., Osborne C. D., Sutherland R. Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob Agents Chemother. 1977 Jun;11(6):956–964. doi: 10.1128/aac.11.6.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Courvalin P., Carlier C., Collatz E. Plasmid-mediated resistance to aminocyclitol antibiotics in group D streptococci. J Bacteriol. 1980 Aug;143(2):541–551. doi: 10.1128/jb.143.2.541-551.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. D'Alessandri R. M., McNeely D. J., Kluge R. M. Antibiotic synergy and antagonism against clinical isolates of Klebsiella species. Antimicrob Agents Chemother. 1976 Dec;10(6):889–892. doi: 10.1128/aac.10.6.889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Davies M., Morgan J. R., Anand C. Interactions of carbenicillin and ticarcillin with gentamicin. Antimicrob Agents Chemother. 1975 Apr;7(4):431–434. doi: 10.1128/aac.7.4.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. De Jongh C. A., Joshi J. H., Newman K. A., Moody M. R., Wharton R., Standiford H. C., Schimpff S. C. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med. 1986 May 30;80(5C):96–100. [PubMed] [Google Scholar]
  41. De Jongh C. A., Joshi J. H., Thompson B. W., Newman K. A., Finley R. S., Moody M. R., Salvatore P. C., Tenney J. H., Drusano G. L., Schimpff S. C. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1986 May 30;80(5C):101–111. [PubMed] [Google Scholar]
  42. DeJace P., Klastersky J. Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside. Am J Med. 1986 Jun 30;80(6B):29–38. doi: 10.1016/0002-9343(86)90476-6. [DOI] [PubMed] [Google Scholar]
  43. Deveikis A., Schauf V., Mizen M., Riff L. Antimicrobial therapy of experimental group B streptococcal infection in mice. Antimicrob Agents Chemother. 1977 May;11(5):817–820. doi: 10.1128/aac.11.5.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Drake T. A., Hackbarth C. J., Sande M. A. Value of serum tests in combined drug therapy of endocarditis. Antimicrob Agents Chemother. 1983 Nov;24(5):653–657. doi: 10.1128/aac.24.5.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. ELION G. B., SINGER S., HITCHINGS G. H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem. 1954 Jun;208(2):477–488. [PubMed] [Google Scholar]
  46. Ein M. E., Smith N. J., Aruffo J. F., Heerema M. S., Bradshaw M. W., Williams T. W., Jr Susceptibility and synergy studies of methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 1979 Nov;16(5):655–659. doi: 10.1128/aac.16.5.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Eliopoulos G. M., Farber B. F., Murray B. E., Wennersten C., Moellering R. C., Jr Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother. 1984 Mar;25(3):398–399. doi: 10.1128/aac.25.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Eliopoulos G. M., Moellering R. C., Jr Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect Dis. 1982 Mar-Apr;4(2):282–293. doi: 10.1093/clinids/4.2.282. [DOI] [PubMed] [Google Scholar]
  49. Eliopoulos G. M., Moellering R. C., Jr Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother. 1981 May;19(5):789–793. doi: 10.1128/aac.19.5.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Eng R. H., Smith S. M., Cherubin C. E. In-vitro emergence of beta-lactam-resistant variants of Pseudomonas aeruginosa. J Antimicrob Chemother. 1986 Jun;17(6):717–723. doi: 10.1093/jac/17.6.717. [DOI] [PubMed] [Google Scholar]
  51. Enzler M. J., Rouse M. S., Henry N. K., Geraci J. E., Wilson W. R. In vitro and in vivo studies of streptomycin-resistant, penicillin-susceptible streptococci from patients with infective endocarditis. J Infect Dis. 1987 May;155(5):954–958. doi: 10.1093/infdis/155.5.954. [DOI] [PubMed] [Google Scholar]
  52. Farber B. F., Eliopoulos G. M., Ward J. I., Ruoff K., Moellering R. C., Jr Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother. 1983 Dec;24(6):871–875. doi: 10.1128/aac.24.6.871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Farber B. F., Yee Y. High-level aminoglycoside resistance mediated by aminoglycoside-modifying enzymes among viridans streptococci: implications for the therapy for endocarditis. J Infect Dis. 1987 May;155(5):948–953. doi: 10.1093/infdis/155.5.948. [DOI] [PubMed] [Google Scholar]
  54. Fass R. J. Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli. Antimicrob Agents Chemother. 1982 Jun;21(6):1003–1006. doi: 10.1128/aac.21.6.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Faville R. J., Jr, Zaske D. E., Kaplan E. L., Crossley K., Sabath L. D., Quie P. G. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA. 1978 Oct 27;240(18):1963–1965. doi: 10.1001/jama.240.18.1963. [DOI] [PubMed] [Google Scholar]
  56. Fu K. P., Hetzel N., Hung P. P., Gregory F. J. Synergistic activity of apalcillin and gentamicin in a combination therapy in experimental Pseudomonas bacteraemia of neutropenic mice. J Antimicrob Chemother. 1986 Apr;17(4):499–503. doi: 10.1093/jac/17.4.499. [DOI] [PubMed] [Google Scholar]
  57. Gates M. L., Sanders C. C., Goering R. V., Sanders W. E., Jr Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1986 Sep;30(3):453–457. doi: 10.1128/aac.30.3.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Gerber A. U., Vastola A. P., Brandel J., Craig W. A. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis. 1982 Nov;146(5):691–697. doi: 10.1093/infdis/146.5.691. [DOI] [PubMed] [Google Scholar]
  59. Glew R. H., Moellering R. C., Jr Effect of protein binding on the activity of penicillins in combination with gentamicin against enterococci. Antimicrob Agents Chemother. 1979 Jan;15(1):87–92. doi: 10.1128/aac.15.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Glew R. H., Pavuk R. A. Early synergistic interaction between semisynthetic penicillins and aminoglycosidic aminocyclitols against Enterobacteriaceae. Antimicrob Agents Chemother. 1983 Jun;23(6):902–906. doi: 10.1128/aac.23.6.902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Glew R. H., Pavuk R. A. Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae. Antimicrob Agents Chemother. 1984 Sep;26(3):378–381. doi: 10.1128/aac.26.3.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Goldstein F. W., Gutmann L., Williamson R., Collatz E., Acar J. F. In vivo and in vitro emergence of simultaneous resistance to both beta-lactam and aminoglycoside antibiotics in a strain of Serratia marcescens. Ann Microbiol (Paris) 1983 May-Jun;134A(3):329–337. [PubMed] [Google Scholar]
  63. Gombert M. E., Aulicino T. M. Amikacin synergism with beta-lactam antibiotics against selected nosocomial pathogens. J Antimicrob Chemother. 1986 Mar;17(3):323–326. doi: 10.1093/jac/17.3.323. [DOI] [PubMed] [Google Scholar]
  64. Gordin F. M., Sande M. A. Amdinocillin therapy of experimental animal infections. Am J Med. 1983 Aug 29;75(2A):48–53. doi: 10.1016/0002-9343(83)90093-1. [DOI] [PubMed] [Google Scholar]
  65. Gribble M. J., Chow A. W., Naiman S. C., Smith J. A., Bowie W. R., Sacks S. L., Grossman L., Buskard N., Growe G. H., Plenderleith L. H. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother. 1983 Sep;24(3):388–393. doi: 10.1128/aac.24.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Gutmann L., Vincent S., Billot-Klein D., Acar J. F., Mrèna E., Williamson R. Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some beta-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam). Antimicrob Agents Chemother. 1986 Dec;30(6):906–912. doi: 10.1128/aac.30.6.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Gutmann L., Williamson R., Kitzis M. D., Acar J. F. Synergism and antagonism in double beta-lactam antibiotic combinations. Am J Med. 1986 May 30;80(5C):21–29. [PubMed] [Google Scholar]
  68. Hackbarth C. J., Chambers H. F., Sande M. A. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Apr;29(4):611–613. doi: 10.1128/aac.29.4.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Hamilton-Miller J. M. Rationalization of terminology and methodology in the study of antibiotic interaction. J Antimicrob Chemother. 1985 Jun;15(6):655–658. doi: 10.1093/jac/15.6.655. [DOI] [PubMed] [Google Scholar]
  70. Hancock R. E., Raffle V. J., Nicas T. I. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1981 May;19(5):777–785. doi: 10.1128/aac.19.5.777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Hancock R. E., Wong P. G. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother. 1984 Jul;26(1):48–52. doi: 10.1128/aac.26.1.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Handwerger S., Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis. 1985 May-Jun;7(3):368–386. doi: 10.1093/clinids/7.3.368. [DOI] [PubMed] [Google Scholar]
  73. Harvey R. J. Synergism in the folate pathway. Rev Infect Dis. 1982 Mar-Apr;4(2):255–260. doi: 10.1093/clinids/4.2.255. [DOI] [PubMed] [Google Scholar]
  74. Heineman H. S., Lofton W. M. Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitro. Antimicrob Agents Chemother. 1978 May;13(5):827–831. doi: 10.1128/aac.13.5.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Heritage J., Settle J. A., Lalani E. N., Lacey R. W. Probable chromosomal mutation to resistance to all aminoglycosides in Staphylococcus aureus selected by the therapeutic use of gentamicin: a preliminary report. J Antimicrob Chemother. 1986 May;17(5):571–574. doi: 10.1093/jac/17.5.571. [DOI] [PubMed] [Google Scholar]
  76. Horodniceanu T., Bougueleret L., El-Solh N., Bieth G., Delbos F. High-level, plasmid-borne resistance to gentamicin in Streptococcus faecalis subsp. zymogenes. Antimicrob Agents Chemother. 1979 Nov;16(5):686–689. doi: 10.1128/aac.16.5.686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Horodniceanu T., Buu-Hoï A., Delbos F., Bieth G. High-level aminoglycoside resistance in group A, B, G, D (Streptococcus bovis), and viridans streptococci. Antimicrob Agents Chemother. 1982 Jan;21(1):176–179. doi: 10.1128/aac.21.1.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Horodniceanu T., Delbos F. Les streptocoques non groupables dans les infections humaines: identification et sensibilité aux antibiotiques. Ann Microbiol (Paris) 1982 Sep-Oct;133(2):255–269. [PubMed] [Google Scholar]
  79. Horrevorts A. M., de Ridder C. M., Poot M. C., de Jonge M. J., Degener J. E., Dzoljic-Danilovic G., Michel M. F., Kerrebijn K. F. Chequerboard titrations: the influence of the composition of serial dilutions of antibiotics on the fractional inhibitory concentration index and fractional bactericidal concentration index. J Antimicrob Chemother. 1987 Jan;19(1):119–125. doi: 10.1093/jac/19.1.119. [DOI] [PubMed] [Google Scholar]
  80. Jawetz E., Gunnison J. B., Coleman V. R. The Combined Action of Penicillin with Streptomycin or Chloromycetin on Enterococci in Vitro. Science. 1950 Mar 10;111(2880):254–256. doi: 10.1126/science.111.2880.254. [DOI] [PubMed] [Google Scholar]
  81. Johnson D. E., Thompson B. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. Am J Med. 1986 May 30;80(5C):53–58. [PubMed] [Google Scholar]
  82. Jones P. G., Rolston K. V., Fainstein V., Elting L., Walters R. S., Bodey G. P. Aztreonam therapy in neutropenic patients with cancer. Am J Med. 1986 Aug;81(2):243–248. doi: 10.1016/0002-9343(86)90258-5. [DOI] [PubMed] [Google Scholar]
  83. Jones R. N., Packer R. R. Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins. Antimicrob Agents Chemother. 1982 Dec;22(6):985–989. doi: 10.1128/aac.22.6.985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. King J. W., Beam T. R., Jr, Neu H. C., Smith L. G. Systemic infections treated with amdinocillin in combination with other beta-lactam antibiotics. Am J Med. 1983 Aug 29;75(2A):90–95. doi: 10.1016/0002-9343(83)90101-8. [DOI] [PubMed] [Google Scholar]
  85. King T. C., Krogstad D. J. Spectrophotometric assessment of dose-response curves for single antimicrobial agents and antimicrobial combinations. J Infect Dis. 1983 Apr;147(4):758–764. doi: 10.1093/infdis/147.4.758. [DOI] [PubMed] [Google Scholar]
  86. Klastersky J., Meunier-Carpentier F., Prevost J. M. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci. 1977 Mar-Apr;273(2):157–167. doi: 10.1097/00000441-197703000-00005. [DOI] [PubMed] [Google Scholar]
  87. Klastersky J., Meunier-Carpentier F., Prevost J. M., Staquet M. Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum. J Infect Dis. 1976 Sep;134(3):271–276. doi: 10.1093/infdis/134.3.271. [DOI] [PubMed] [Google Scholar]
  88. Klastersky J., Zinner S. H. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis. 1982 Mar-Apr;4(2):294–301. doi: 10.1093/clinids/4.2.294. [DOI] [PubMed] [Google Scholar]
  89. Kluge R. M., Standiford H. C., Tatem B., Young V. M., Schimpff S. C., Greene W. H., Calia F. M., Hornick R. B. The carbenicillin-gentamicin combination against Pseudomonas aeruginosa. Correlation of effect with gentamicin sensitivity. Ann Intern Med. 1974 Nov;81(5):584–587. doi: 10.7326/0003-4819-81-5-584. [DOI] [PubMed] [Google Scholar]
  90. Korzeniowski O., Sande M. A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med. 1982 Oct;97(4):496–503. doi: 10.7326/0003-4819-97-4-496. [DOI] [PubMed] [Google Scholar]
  91. Kramer B. S., Ramphal R., Rand K. H. Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother. 1986 Jul;30(1):64–68. doi: 10.1128/aac.30.1.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Krogstad D. J., Korfhagen T. R., Moellering R. C., Jr, Wennersten C., Swartz M. N. Plasmid-mediated resistance to antibiotic synergism in enterococci. J Clin Invest. 1978 Jun;61(6):1645–1653. doi: 10.1172/JCI109085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Kuck N. A., Testa R. T., Forbes M. In vitro and in vivo antibacterial effects of combinations of beta-lactam antibiotics. Antimicrob Agents Chemother. 1981 Apr;19(4):634–638. doi: 10.1128/aac.19.4.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Kurtz T. O., Winston D. J., Bruckner D. A., Martin W. J. Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens. Antimicrob Agents Chemother. 1981 Aug;20(2):239–243. doi: 10.1128/aac.20.2.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. LEPPER M. H., DOWLING H. F. Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. AMA Arch Intern Med. 1951 Oct;88(4):489–494. doi: 10.1001/archinte.1951.03810100073006. [DOI] [PubMed] [Google Scholar]
  96. Levison M. E., Kobasa W. D. Mezlocillin and ticarcillin alone and combined with gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis. Antimicrob Agents Chemother. 1984 Jun;25(6):683–686. doi: 10.1128/aac.25.6.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Levy J., Klastersky J. Synergism between amikacin and cefazolin against Staphylococcus aureus: a comparative study of oxacillin-sensitive and oxacillin-resistant strains. J Antimicrob Chemother. 1979 Jul;5(4):365–373. doi: 10.1093/jac/5.4.365. [DOI] [PubMed] [Google Scholar]
  98. Loh B., Grant C., Hancock R. E. Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Oct;26(4):546–551. doi: 10.1128/aac.26.4.546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Love L. J., Schimpff S. C., Schiffer C. A., Wiernik P. H. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med. 1980 May;68(5):643–648. doi: 10.1016/0002-9343(80)90243-0. [DOI] [PubMed] [Google Scholar]
  100. Lowy F. D., Hammer S. M. Staphylococcus epidermidis infections. Ann Intern Med. 1983 Dec;99(6):834–839. doi: 10.7326/0003-4819-99-6-834. [DOI] [PubMed] [Google Scholar]
  101. Lyon M. D., Smith K. R., Saag M. S., Cloud G. A., Cobbs C. G. In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1986 Jul;30(1):25–30. doi: 10.1128/aac.30.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Martin N. L., Beveridge T. J. Gentamicin interaction with Pseudomonas aeruginosa cell envelope. Antimicrob Agents Chemother. 1986 Jun;29(6):1079–1087. doi: 10.1128/aac.29.6.1079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. McLaughlin F. J., Matthews W. J., Jr, Strieder D. J., Sullivan B., Taneja A., Murphy P., Goldmann D. A. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis. 1983 Mar;147(3):559–567. doi: 10.1093/infdis/147.3.559. [DOI] [PubMed] [Google Scholar]
  104. Michel J., Bornstein H., Luboshitzky R., Sacks T. Mechanis of chlorampenicol-cephalordine synergism on Enerobacteiaeae. Antimicrob Agents Chemother. 1975 Jun;7(6):845–849. doi: 10.1128/aac.7.6.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Miller M. H., Feinstein S. A., Chow R. T. Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1987 Jan;31(1):108–110. doi: 10.1128/aac.31.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Miller M. H., Wexler M. A., Steigbigel N. H. Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants. Antimicrob Agents Chemother. 1978 Sep;14(3):336–343. doi: 10.1128/aac.14.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Miller M. H., el-Sokkary M. A., Feinstein S. A., Lowy F. D. Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci. Antimicrob Agents Chemother. 1986 Nov;30(5):763–768. doi: 10.1128/aac.30.5.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Mintz L., Drew W. L. Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1981 Feb;19(2):332–334. doi: 10.1128/aac.19.2.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Moellering R. C., Jr Antimicrobial synergism--an elusive concept. J Infect Dis. 1979 Oct;140(4):639–641. doi: 10.1093/infdis/140.4.639. [DOI] [PubMed] [Google Scholar]
  110. Moellering R. C., Jr, Korzeniowski O. M., Sande M. A., Wennersten C. B. Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis. 1979 Aug;140(2):203–208. doi: 10.1093/infdis/140.2.203. [DOI] [PubMed] [Google Scholar]
  111. Moellering R. C., Jr, Medoff G., Leech I., Wennersten C., Kunz L. J. Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother. 1972 Jan;1(1):30–34. doi: 10.1128/aac.1.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Moellering R. C., Jr, Murray B. E., Schoenbaum S. C., Adler J., Wennersten C. B. A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis. J Infect Dis. 1980 Jan;141(1):81–86. doi: 10.1093/infdis/141.1.81. [DOI] [PubMed] [Google Scholar]
  113. Moellering R. C., Jr, Weinberg A. N. Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest. 1971 Dec;50(12):2580–2584. doi: 10.1172/JCI106758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Moellering R. C., Jr, Wennersten C., Weinberg A. N. Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med. 1971 May;77(5):821–828. [PubMed] [Google Scholar]
  115. Moellering R. C., Jr, Willey S., Eliopoulos G. M. Synergism and antagonism of ceftizoxime and other new cephalosporins. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):69–79. doi: 10.1093/jac/10.suppl_c.69. [DOI] [PubMed] [Google Scholar]
  116. Murray B. E., Church D. A., Wanger A., Zscheck K., Levison M. E., Ingerman M. J., Abrutyn E., Mederski-Samoraj B. Comparison of two beta-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother. 1986 Dec;30(6):861–864. doi: 10.1128/aac.30.6.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Murray B. E., Karchmer A. W., Moellering R. C., Jr Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med. 1980 Dec;69(6):838–848. doi: 10.1016/s0002-9343(80)80009-x. [DOI] [PubMed] [Google Scholar]
  118. Murray B. E., Mederski-Samaroj B. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest. 1983 Sep;72(3):1168–1171. doi: 10.1172/JCI111042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Murray B. E., Tsao J., Panida J. Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides. Antimicrob Agents Chemother. 1983 Jun;23(6):799–802. doi: 10.1128/aac.23.6.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Neu H. C., Fu K. P. Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob Agents Chemother. 1978 Nov;14(5):650–655. doi: 10.1128/aac.14.5.650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Neu H. C., Fu K. P. Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins. Antimicrob Agents Chemother. 1978 May;13(5):813–819. doi: 10.1128/aac.13.5.813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Neu H. C. Penicillin-binding proteins and role of amdinocillin in causing bacterial cell death. Am J Med. 1983 Aug 29;75(2A):9–20. doi: 10.1016/0002-9343(83)90089-x. [DOI] [PubMed] [Google Scholar]
  123. Norden C. W., Shaffer M. A. Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Jan;21(1):62–65. doi: 10.1128/aac.21.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Norden C. W., Wentzel H., Keleti E. Comparison of techniques for measurement of in vitro antibiotic synergism. J Infect Dis. 1979 Oct;140(4):629–633. doi: 10.1093/infdis/140.4.629. [DOI] [PubMed] [Google Scholar]
  125. PLOTZ P. H., DAVIS B. D. Synergism between streptomycin and penicillin: a proposed mechanism. Science. 1962 Mar 23;135(3508):1067–1068. doi: 10.1126/science.135.3508.1067. [DOI] [PubMed] [Google Scholar]
  126. Parrillo J. E., Borst G. C., Mazur M. H., Iannini P., Klempner M. S., Moellering R. C., Jr, Anderson S. E. Endocarditis due to resistant viridans streptococci during oral penicillin chemoprophylaxis. N Engl J Med. 1979 Feb 8;300(6):296–300. doi: 10.1056/NEJM197902083000608. [DOI] [PubMed] [Google Scholar]
  127. Parry M. F., Neu H. C. A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli. Am J Med. 1978 Jun;64(6):961–966. doi: 10.1016/0002-9343(78)90450-3. [DOI] [PubMed] [Google Scholar]
  128. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Pechère J. C., Marchou B., Michéa-Hamzehpour M., Auckenthaler R. Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother. 1986 Mar;17 (Suppl A):11–18. doi: 10.1093/jac/17.suppl_a.11. [DOI] [PubMed] [Google Scholar]
  130. Piccart M., Klastersky J., Meunier F., Lagast H., Van Laethem Y., Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984 Dec;26(6):870–875. doi: 10.1128/aac.26.6.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Pickering L. K., Rutherford I. Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin and piperacillin. J Pharmacol Exp Ther. 1981 May;217(2):345–349. [PubMed] [Google Scholar]
  132. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  133. Reyes M. P., El-Khatib M. R., Brown W. J., Smith F., Lerner A. M. Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J Infect Dis. 1979 Aug;140(2):192–202. doi: 10.1093/infdis/140.2.192. [DOI] [PubMed] [Google Scholar]
  134. Riff L. J., Jackson G. G. Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Arch Intern Med. 1972 Dec;130(6):887–891. [PubMed] [Google Scholar]
  135. Rolston K. V., Jones P. G., Fainstein V., Elting L., Bodey G. P. Ceftizoxime plus ticarcillin: double beta-lactam therapy for infections in cancer patients. J Antimicrob Chemother. 1987 Mar;19(3):367–371. doi: 10.1093/jac/19.3.367. [DOI] [PubMed] [Google Scholar]
  136. Rusnak M. G., Drake T. A., Hackbarth C. J., Sande M. A. Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs. J Infect Dis. 1984 Jun;149(6):980–985. doi: 10.1093/infdis/149.6.980. [DOI] [PubMed] [Google Scholar]
  137. Ryan R. W., Kwasnik I., Tilton R. C. Methodological variation in antibiotic synergy tests against enterococci. J Clin Microbiol. 1981 Jan;13(1):73–75. doi: 10.1128/jcm.13.1.73-75.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Sabath L. D., Elder H. A., McCall C. E., Finland M. Synergistic combinations of penicillins in the treatment of bacteriuria. N Engl J Med. 1967 Aug 3;277(5):232–238. doi: 10.1056/NEJM196708032770503. [DOI] [PubMed] [Google Scholar]
  139. Sande M. A., Courtney K. B. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J Lab Clin Med. 1976 Jul;88(1):118–124. [PubMed] [Google Scholar]
  140. Sande M. A., Irvin R. G. Penicillin-aminoglycoside synergy in experimental Streptococcus viridans endocarditis. J Infect Dis. 1974 May;129(5):572–576. doi: 10.1093/infdis/129.5.572. [DOI] [PubMed] [Google Scholar]
  141. Sande M. A., Scheld W. M. Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med. 1980 Mar;92(3):390–395. doi: 10.7326/0003-4819-92-3-390. [DOI] [PubMed] [Google Scholar]
  142. Sanders C. C., Sanders W. E., Jr, Goering R. V. Influence of clindamycin on derepression of beta-lactamases in Enterobacter spp. and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1983 Jul;24(1):48–53. doi: 10.1128/aac.24.1.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Sattler F. R., Remington J. S. Another look at trimethoprim-sulfamethoxazole: its role in parenteral therapy. Eur J Clin Microbiol. 1984 Jun;3(3):174–176. doi: 10.1007/BF02014872. [DOI] [PubMed] [Google Scholar]
  144. Sattler F. R., Remington J. S. Intravenous sulfamethoxazole and trimethoprim for serious gram-negative bacillary infection. Arch Intern Med. 1983 Sep;143(9):1709–1712. [PubMed] [Google Scholar]
  145. Scudamore R. A., Goldner M. Penetration of the outer membrane of Pseudomonas aeruginosa by synergistic combinations of beta-lactam and aminoglycoside antibiotics. Antimicrob Agents Chemother. 1982 Jun;21(6):1007–1010. doi: 10.1128/aac.21.6.1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]
  147. Shapiro S., Siskind V., Slone D., Lewis G. P., Jick H. Drug rash with ampicillin and other penicillins. Lancet. 1969 Nov 8;2(7628):969–972. doi: 10.1016/s0140-6736(69)90535-2. [DOI] [PubMed] [Google Scholar]
  148. Solomkin J. S., Fant W. K., Rivera J. O., Alexander J. W. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med. 1985 Jun 7;78(6A):85–91. doi: 10.1016/0002-9343(85)90106-8. [DOI] [PubMed] [Google Scholar]
  149. Spitzer P. G., Eliopoulos G. M., Karchmer A. W., Moellering R. C., Jr Comparative in vitro activity of the new cyclic lipopeptide LY146032 against Corynebacterium species. Eur J Clin Microbiol. 1987 Apr;6(2):183–185. doi: 10.1007/BF02018205. [DOI] [PubMed] [Google Scholar]
  150. Standiford H. D., De Maine J. B., Kirby W. M. Antibiotic synergism of enterococci. Relation to inhibitory concentrations. Arch Intern Med. 1970 Aug;126(2):255–259. [PubMed] [Google Scholar]
  151. Thauvin C., Eliopoulos G. M., Wennersten C., Moellering R. C., Jr Antagonistic effect of penicillin-amikacin combinations against enterococci. Antimicrob Agents Chemother. 1985 Jul;28(1):78–83. doi: 10.1128/aac.28.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Tomasz A. From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view. Rev Infect Dis. 1979 May-Jun;1(3):434–467. doi: 10.1093/clinids/1.3.434. [DOI] [PubMed] [Google Scholar]
  153. Tomasz A., de Vegvar M. L. Construction of a penicillin-tolerant laboratory mutant of Staphylococcus aureus. Eur J Clin Microbiol. 1986 Dec;5(6):710–713. doi: 10.1007/BF02013310. [DOI] [PubMed] [Google Scholar]
  154. Utsui Y., Ohya S., Magaribuchi T., Tajima M., Yokota T. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Dec;30(6):917–922. doi: 10.1128/aac.30.6.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Van Laethem Y., Klastersky J. Serum bactericidal activity of mezlocillin, ceftazidime, mezlocillin/ceftazidime and mezlocillin/amikacin against Klebsiella pneumoniae and Pseudomonas aeruginosa. Eur J Clin Microbiol. 1986 Feb;5(1):110–114. doi: 10.1007/BF02013479. [DOI] [PubMed] [Google Scholar]
  156. Van Landuyt H. W., Pyckavet M., Lambert A. M. Comparative activity of BRL 25.000 with amoxycillin against resistant clinical isolates. J Antimicrob Chemother. 1981 Jan;7(1):65–70. doi: 10.1093/jac/7.1.65. [DOI] [PubMed] [Google Scholar]
  157. Van der Auwera P., Klastersky J., Thys J. P., Meunier-Carpentier F., Legrand J. C. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother. 1985 Oct;28(4):467–472. doi: 10.1128/aac.28.4.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Wald E. R., Standiford H. C., Tatem B. A., Calia F. M., Hornick R. B. BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1975 Mar;7(3):336–340. doi: 10.1128/aac.7.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Wallace S. M., Chan L. Y. In vitro interaction of aminoglycosides with beta-lactam penicillins. Antimicrob Agents Chemother. 1985 Aug;28(2):274–281. doi: 10.1128/aac.28.2.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Washington J. A., 2nd The clinical microbiology laboratory. Utilization and cost-effectiveness. Am J Med. 1985 Jun 28;78(6B):8–16. doi: 10.1016/0002-9343(85)90357-2. [DOI] [PubMed] [Google Scholar]
  161. Watanakunakorm C., Glotzbecker C. Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother. 1974 Dec;6(6):802–806. doi: 10.1128/aac.6.6.802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Watanakunakorn C. Effects of inoculum size on the activity of carboxy- and ureido-penicillins and effects of combinations of ureido-penicillins with aminoglycosides against resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 1986 Jan;17(1):91–95. doi: 10.1093/jac/17.1.91. [DOI] [PubMed] [Google Scholar]
  163. Wilson W. R., Thompson R. L., Wilkowske C. J., Washington J. A., 2nd, Giuliani E. R., Geraci J. E. Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin. JAMA. 1981 Jan 23;245(4):360–363. [PubMed] [Google Scholar]
  164. Wilson W. R., Zak O., Sande M. A. Penicillin therapy for treatment of experimental endocarditis caused by viridans streptococci in animals. J Infect Dis. 1985 Jun;151(6):1028–1033. doi: 10.1093/infdis/151.6.1028. [DOI] [PubMed] [Google Scholar]
  165. Winston D. J., Barnes R. C., Ho W. G., Young L. S., Champlin R. E., Gale R. P. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med. 1984 Sep;77(3):442–450. doi: 10.1016/0002-9343(84)90100-1. [DOI] [PubMed] [Google Scholar]
  166. Wise R., Andrews J. M. In vitro activity of fludalanine combined with pentizidone compared with those of other agents. Antimicrob Agents Chemother. 1984 May;25(5):612–617. doi: 10.1128/aac.25.5.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Wise R. beta-Lactamase inhibitors. J Antimicrob Chemother. 1982 Feb;9 (Suppl B):31–40. doi: 10.1093/jac/9.suppl_b.31. [DOI] [PubMed] [Google Scholar]
  168. Wolfson J. S., Swartz M. N. Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med. 1985 Apr 11;312(15):968–975. doi: 10.1056/NEJM198504113121507. [DOI] [PubMed] [Google Scholar]
  169. Yee Y., Farber B., Mates S. Mechanism of penicillin-streptomycin synergy for clinical isolates of viridans streptococci. J Infect Dis. 1986 Sep;154(3):531–534. doi: 10.1093/infdis/154.3.531. [DOI] [PubMed] [Google Scholar]
  170. Yu P. K., Edson R. S., Washington J. A., 2nd, Hermans P. E. Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1983 Jan;23(1):179–181. doi: 10.1128/aac.23.1.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Zenilman J. M., Miller M. H., Mandel L. J. In vitro studies simultaneously examining effect of oxacillin on uptake of radiolabeled streptomycin and on associated bacterial lethality in Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Dec;30(6):877–882. doi: 10.1128/aac.30.6.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Zervos M. J., Kauffman C. A., Therasse P. M., Bergman A. G., Mikesell T. S., Schaberg D. R. Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med. 1987 May;106(5):687–691. doi: 10.7326/0003-4819-106-5-687. [DOI] [PubMed] [Google Scholar]
  173. Zimmermann R. A., Moellering R. C., Jr, Weinberg A. N. Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol. 1971 Mar;105(3):873–879. doi: 10.1128/jb.105.3.873-879.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Zuravleff J. J., Yu V. L., Yee R. B., Zaphyr M. K., Diven W., Taylor F. B. Effect of calcium, magnesium, and zinc on ticarcillin and tobramycin alone and in combination against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Nov;22(5):839–843. doi: 10.1128/aac.22.5.839. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES